Angiotensin Receptor Blockers in Aortic Stenosis
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age20-99
SponsorInstitut universitaire de cardiologie et de pneumologie de Québec, University Laval
About this trial
This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.
Eligibility criteria
Qualifiers
Mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and <4m/s)
Normal left ventricular ejection fraction (i.e. ≥50%)
Systolic blood pressure >110 mmHg
Diastolic blood pressure >70 mmHg
Disqualifiers
More than mild aortic or mitral regurgitation, or mitral stenosis
Current use or documented indication for renin-angiotensin system medication or Aliskiren
Known allergy or intolerance to angiotensin II receptor blockers (ARBs)
Alzheimer, dementia or known non-compliant patient
Trial design
Treatments tested in this trial
- Angiotensin Receptor Blockers
- Placebo
Treatment groups
144 Participants
are divided into 2 treatment groupsSponsors and collaborators
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Lead sponsor
Odense University Hospital
Collaborator
Source ClinicalTrials.gov